Alternating combination chemotherapy COP (cyclophosphamide, vincristine, prednisone) and MP (melphalan, prednisone) in multiple myeloma: A multicenter phase II study (JCOG8906)

Japanese Journal of Clinical Oncology

Volumn 29, Issue 10, 1999, Pages 485-489

  Takenaka, Takeaki ^a   Shirakawa, Shigeru ^b   Mikuni, Chikara ^c   Sai, Toshiaki ^d   Shimamoto, Yoshinori ^e   Araki, Koichi ^f   Hirano, Masami ^g   Miura, Akira ^h   Ohno, Yoh Ichiro ⁱ   Ichimaru, Michito ^j   Hanada, Shu Ichi ^k   Inaba, Satoshi ^l   Konishi, Hiroshi ^m   Toki, Hironobu ⁿ   Tajima, Kinuko ^a   Niimi, Miyuki ^o   Fukuda, Haruhiko ^o   Shimoyama, Masanori ^a,p  

^a NATIONAL CANCER CENTER HOSPITAL   (Japan)

^b MIE UNIVERSITY   (Japan)

^c HOKKAIDO CANCER CENTER   (Japan)

^d Iwaki Kyoritsu General Hospital   (Japan)

^e SAGA UNIVERSITY   (Japan)

^f UNIVERSITY OF THE RYUKYUS   (Japan)

^g FUJITA HEALTH UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^h AKITA UNIVERSITY   (Japan)

ⁱ TENRI HOSPITAL   (Japan)

^j NAGASAKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^k KAGOSHIMA UNIVERSITY   (Japan)

^l JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^m KURASHIKI CENTRAL HOSPITAL   (Japan)

ⁿ NATIONAL HOSPITAL ORGANIZATION SHIKOKU CANCER CENTER   (Japan)

^o NATIONAL CANCER CENTER RESEARCH INSTITUTE   (Japan)

^p NATIONAL HOSPITAL ORGANIZATION NAGOYA MEDICAL CENTER   (Japan)

more..

Author keywords

Combination chemotherapy; COP MP regimen; Multiple myeloma; Phase II study

Indexed keywords

ANTINEOPLASTIC AGENT; AP PROTOCOL 2; COP PROTOCOL 2; CYCLOPHOSPHAMIDE; MELPHALAN; PREDNISONE; VINCRISTINE;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; DRUG ADMINISTRATION; DRUG SCREENING; FEMALE; HUMAN; MALE; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; MULTIPLE MYELOMA; PHASE 2 CLINICAL TRIAL; SURVIVAL RATE;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYCLOPHOSPHAMIDE; DRUG ADMINISTRATION SCHEDULE; DRUG EVALUATION; FEMALE; HUMANS; MALE; MELPHALAN; MIDDLE AGED; MULTIPLE MYELOMA; PREDNISONE; SURVIVAL RATE; VINCRISTINE;

EID: 0033202084     PISSN: 03682811     EISSN: None     Source Type: Journal    
DOI: 10.1093/jjco/29.10.485     Document Type: Article

References (34)

1. Feinleib M, MacMahon B. Duration of survival in multiple myeloma. J Natl Cancer Inst 1960;14:1259-69.
2. Osgood EE. The survival time of patients with plasmocytic myeloma. Cancer Chemother Rep 1960;9:1-10.
3. Alexanian R, Haut A, Khan AU, Lane M, McKelvey EM, Migliore PJ, et al. Treatment for multiple myeloma: combination chemotherapy with different melphalan dose regimens. J Am Med Assoc 1969;208:1680-5.
4. Bergsagel DE. Chemotherapy of myeloma: drug combinations versus single agents, an overview and comments on acute leukemia in myeloma. Haematol Oncol 1988;6:159-66.
5. Bergsagel DE. Controversies in the treatment of plasma cell myeloma. Postgrad Med J 1985;61:109-16.
6. Rivers SL, Patno ME. Cyclophosphamide vs melphalan in treatment of plasma cell myeloma. J Am Med Assoc 1969;207:1328-34.
7. Salmon SE. Expansion of the growth fraction in multiple myeloma with alkylating agents. Blood 1975;45:119-29.
8. Alexanian R, Salmon S, Bonnet J, Gehan E, Haut A, Weick J. Combination therapy for multiple myeloma. Cancer 1977;40:2765-71.
9. Alexanian R, Salmon S, Gutterman J, Dixon D, Bonnet J, Haut A. Chemoimmunotherapy for multiple myeloma. Cancer 1981;47:1923-9.
10. Ogawa M, Bergsagel DE, McCulloch EA. Chemotherapy of mouse myeloma: quantitative cell cultures predictive of response in vivo. Blood 1973;41:7-15.
11. Bergsagel DE, Cowan DH, Hasselback R. Plasma cell myeloma: response of melphalan-resistant patients to high-dose intermittent cyclophosphamide. Can Med Assoc J 1972;107:851-5.
12. Durie BGM. Staging and kinetics of myeloma. Semin Oncol 1986;13:300-9.
13. Salmon SE, Haut A, Bonnet JD, Amare M, Weick JK, Durie BGM, et al. Alternating combination chemotherapy and levamisole improves survival in multiple myeloma: a Southwest Oncology Group Study. J Clin Oncol 1983;1:453-61.
14. Oken MM, Davis TE, Creech RH, McFadden ET, Tormey DC, Carbone PP, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982;5:649-55.
15. World Health Organization. WHO Handbook for Reporting Results of Cancer Treatment. WHO Offset Publication No. 48. Geneva: WHO 1979.
16. Kaplan EL, Meier P. Non-parametric estimation for incomplete observations. J Am Stat Assoc 1958;53:457-81.
17. Anderson KC. Who benefits from high-dose therapy for multiple myeloma? J Clin Oncol 1995;13:1291-6.
18. Kovacsovics TJ, Delaly A. Intensive treatment strategies in multiple myeloma. Semin Hematol 1997;34(Suppl 1):49-60.
19. Bensinger WI, Demirer T, Buckner CD, Appelbaum FR, Storb R, Lilleb K, et al. Syngeneic marrow transplantation in patients with multiple myeloma. Bone Marrow Transplant 1996;18:527-31.
20. Gahrton G, Tura S, Ljungman P, Belanger C, Brandt L, Cavo M, et al. Allogeneic bone marrow transplantation in multiple myeloma. N Engl J Med 1991;325:1267-73.
21. Attal M, Harousseau JL, Stoppa AM, Sotto JJ, Fuzibet JG, Rossi JF, et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. N Engl J Med 1996;335:91-7.
22. Barlogie B, Jagannath S, Vesole DH, Naucke S, Cheson B, Mattox S, et al. Superiority of tandem autologous transplantation over standard therapy for previously untreated multiple myeloma. Blood 1997;89:779-93.
23. Harley JB, Pajak TF, McIntyre OR, Kochwa S, Cooper MR, Coleman M, et al. Improved survival of increased-risk myeloma patients on combined triple-alkylating-agent therapy;a study of the CALGB. Blood 1979;54:13-22.
24. Bergsagel DE, Bailey AJ, Langley GR, MacDonald RN, White DF, Miller AB. The chemotherapy of plasma-cell myeloma and the incidence of acute leukemia. N Engl J Med 1979;301:743-8.
25. Cavagnaro F, Lein JM, Pavlovsky S, Becherini JO, Pileggi JE, Micheo EQ, et al. Comparison of two combination chemotherapy regimens for multiple myeloma: methyl-CCNU, cyclophosphamide and prednisone versus melphalan and prednisone. Cancer Treat Rep 1980;64:73-9.
26. Abramson N, Lurie P, Mietlowski WL, Schilling A, Bennett JM, Horton J. Phase III study of intermittent carmustine (BCNU), cyclophosphamide and prednisone versus intermittent melphalan and prednisone in myeloma. Cancer Treat Rep. 1982;66:1273-7.
27. Alexanian R, Dreicer R. Chemotherapy for multiple myeloma. Cancer 1984;53:583-8.
28. Pavlovsky S, Corrado C, Santarelli MT, Saslavsky J, Cavagnaro F, Palau M, et al. An update of two randomized trials in previously untreated multiple myeloma comparing melphalan and prednisone versus three- and five- drug combinations: an Argentine group for the treatment of acute leukemia study. J Clin Oncol 1988;6:769-75.
29. MacLennan ICM, Kelly K, Crockson RA, Cooper EH, Cuzick J, Chapman C. Results of the MRC myelomatosis trials for patients entered since 1980. Hematol Oncol 1988;6:145-58.
30. Peest D, Deicher H, Coldewey R, Schmoll HJ, Schedel I. Induction and maintenance therapy in multiple myeloma;a multicenter trial of MP versus VCMP. Eur J Cancer Clin Oncol 1988;24:1061-7.
31. Boccadoro M, Marmont F, Tribalto M, Avvisati G, Andriani A, Barbui T, et al. Multiple myeloma: VMCP/VBAP alternating combination chemotherapy is not superior to melphalan and prednisone even in high-risk patients. J Clin Oncol 1991;9:444-8.
32. Bladé J, Miguel JFS, Alcalá A, Maldonado J, Sanz MA, Garcia-Conde J, et al. Alternating combination VCMP/VBAP chemotherapy versus melphalan/ prednisone in the treatment of multiple myeloma: a randomized multicentric study of 487 patients. J Clin Oncol 1993;11:1165-71.
33. Gregory WM, Richards MA, Malpas JS. Combination chemotherapy versus melphalan and prednisolone in the treatment of multiple myeloma: an overview of published trials. J Clin Oncol 1992;10:334-42.
34. Shachor J, Beker B, Geffen Y, Bruderman I. Acute ECG changes during cyclophosphamide infusion in a patient with bronchogenic carcinoma. Cancer Treat Rep 1985;69:734-5.